Company Description
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne.
The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation.
Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Nov 12, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Claude Maraoui |
Contact Details
Address: 9237 East Via de Ventura Boulevard, Suite 105 Scottsdale, Arizona 85258 United States | |
| Phone | 480 434 6670 |
| Website | journeymedicalcorp.com |
Stock Details
| Ticker Symbol | DERM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001867066 |
| CUSIP Number | 48115J109 |
| ISIN Number | US48115J1097 |
| Employer ID | 47-1879539 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Claude Maraoui | Founder, President, Chief Executive Officer and Director |
| Dr. Lindsay Allan Rosenwald | Executive Chairman |
| Joseph M. Benesch | Chief Financial Officer and Corporate Controller |
| Andrew J. Zwible | Vice President of Operations |
| Ramsey Alloush | General Counsel and Company Secretary |
| Robert Nevin | Chief Commercial Officer |
| Jaclyn Jaffe | Senior Director of Corporate Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 4, 2024 | 8-K | Current Report |
| Sep 9, 2024 | UPLOAD | Filing |
| Aug 21, 2024 | UPLOAD | Filing |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |
| Jul 19, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 12, 2024 | 8-K | Current Report |